ScientiaCME Who ‘nose’ the best path forward? Improving awareness and optimizing the management of recurrent or metastatic nasopharyngeal carcinoma
In this online, self-learning activity:
Nasopharyngeal carcinoma (NPC) is a rare form of head and neck cancer, with 133,000-176,000 new cases diagnosed worldwide each year. Although relatively uncommon in the United States with an age-standardized incidence rate of 0.41 per 100,000 population, NPC is endemic to certain geographic regions, such as southern China, Southeast Asia, and North Africa. Several risk factors for NPC have been identified, including consumption of salted fish, alcohol use, wood dust exposure, and plasma Epstein–Barr virus positivity.
Cost: Free
View Offer chevron_rightDetails
In this online, self-learning activity:
Nasopharyngeal carcinoma (NPC) is a rare form of head and neck cancer, with 133,000-176,000 new cases diagnosed worldwide each year. Although relatively uncommon in the United States with an age-standardized incidence rate of 0.41 per 100,000 population, NPC is endemic to certain geographic regions, such as southern China, Southeast Asia, and North Africa. Several risk factors for NPC have been identified, including consumption of salted fish, alcohol use, wood dust exposure, and plasma Epstein–Barr virus positivity.
Learning Objectives
By the end of the session the participant will be able to:
- Review risk factors for the development and progression of NPC, including the identification of patients at high risk for distant metastases.
- Compare systemic treatment regimens available for the management of recurrent or metastatic NPC.
- Evaluate the evidence supporting the safety and efficacy of various treatment approaches for recurrent or metastatic NPC.
- Individualize treatment for a patient with metastatic NPC using guideline recommendations and multidisciplinary strategies.
Target Audience
HCPs including but not limited to: medical oncologists, radiation oncologists, and otolaryngologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and any other clinicians who are involved or interested in the treatment of recurrent or metastatic NPC.
Additional credit info
ACCME Activity #203279196
ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABIM MOC Credit Type: Medical Knowledge
Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly. It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.
Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-25-014-H01-P. This is an Application (A)-type activity.

Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurses: This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™, and the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ to meet the continuing education renewal requirements of nursing re-certification for APRNs and RN specialty. Some state nursing boards accept AMA PRA Category 1 Credit(s)™ for re-licensure requirements, some do not. Check your state board of nursing’s CE requirements before applying credit from this course to your re-licensure.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.